TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06157554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: During the exercise sessions, participants will be seated in a chair. In the first five and last five minutes of the session, they will be instructed to focus on their breathing and the sensations produced in the body while sitting comfortably in a relaxed position with all joints in the chairs with their eyes closed. After the initial 5 minutes of relaxed breathing, participants will be instructed to perform diaphragmatic and costal breathing for 10 minutes. After 5 minutes of diaphragmatic breathing, the patient will be rested for 1 minute and then 5 minutes of costal breathing will be performed. While doing coastal breathing, patients will be asked to place their hands on their costas, take a deep breath and inflate the bottom of their hands; then they will be asked to exhale the breath they take in a longer (1:2) time.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment
Description: Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
Study: NCT05694364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3007
Description: PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3007
Description: PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
Study: NCT05100862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
Study: NCT06157554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
Study: NCT05459350

Intervention type: DIAGNOSTIC_TEST
Intervention: Safe Discharge Classification
Description: Safe Discharge Classification
Study: NCT06624878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: 0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
Study: NCT06363591

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wise vs wide
Description: Wise vs wide excisions for thin melanoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wise vs wide
Description: Wise vs wide excisions for thin melanoma
Study: NCT05427487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX037
Description: Bioselected oncolytic RNA virus
Study: NCT06133530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides
Description: Prebiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltose
Description: Control
Study: NCT05522023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group treated with aromatic solution
Description: The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: group treated with drinking water
Description: In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
Study: NCT05427487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX037
Description: Bioselected oncolytic RNA virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: An immune checkpoint inhibitor
Study: NCT06777784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Modern Nicotine Oral Product Cool Mint 12 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: Modern Nicotine Oral Product Cool Mint 12 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine
Study: NCT05273554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV
Study: NCT05022615

Intervention type: DIAGNOSTIC_TEST
Intervention: Topcon Camera
Description: Standard 7 field imaging
Study: NCT05273554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Given by PO
Study: NCT04271306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (10ug)/Matrix-M (50ug)
Description: 3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
Study: NCT06777784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Modern Nicotine Oral Product Cool Mint 15 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine
Study: NCT04271306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (10ug)/Matrix-M (50ug)
Description: 3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (10ug)/Matrix-M (50ug)
Description: 3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (50ug)/Matrix-M (50ug)
Description: 3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (50ug)/Matrix-M (50ug)
Description: 3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)
Description: 2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
Study: NCT05727020

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
Study: NCT05022615

Intervention type: DIAGNOSTIC_TEST
Intervention: Topcon Camera
Description: Standard 7 field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Topcon Camera
Description: Standard 7 field imaging
Study: NCT05727020

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of matched samples of breath, biofluids and pancreatic tissue
Description: In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of matched samples of breath, biofluids and pancreatic tissue
Description: In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
Study: NCT04951856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML
Description: Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
Study: NCT06777784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Modern Nicotine Oral Product Smooth 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: Modern Nicotine Oral Product Wintergreen 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine
Study: NCT05022615

Intervention type: DIAGNOSTIC_TEST
Intervention: Topcon Camera
Description: Standard 7 field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Optos Camera
Description: Ultrawide field imaging
Study: NCT06777784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: Modern Nicotine Oral Product Dragon Fruit 6 mg Nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum
Study: NCT05022615

Intervention type: DIAGNOSTIC_TEST
Intervention: Optos Camera
Description: Ultrawide field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Optos Camera
Description: Ultrawide field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Optos Camera
Description: Ultrawide field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Clarus Camera
Description: Ultrawide field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Clarus Camera
Description: Ultrawide field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Clarus Camera
Description: Ultrawide field imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Clarus Camera
Description: Ultrawide field imaging
Study: NCT05480540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious game
Description: According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Serious game
Description: According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
Study: NCT04243915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program
Description: The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PNMES (introducing the needle) plus motor control exercise program
Description: The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS plus motor control exercise program
Description: Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham PNMES (without inserting the needle) plus motor control exercise program
Description: The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
Study: NCT06777784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum
Study: NCT04348747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-HER2/HER3 Dendritic Cell Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05249933

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8
Description: Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8
Description: Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.